Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $181,125.78 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 1,551 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78. Following the completion of the transaction, the insider now owns 19,544 shares of the company’s stock, valued at $2,282,348.32. This trade represents a 7.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Julie Cooke also recently made the following trade(s):

• On Monday, February 10th, Julie Cooke sold 700 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $118.28, for a total transaction of $82,796.00.
• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.89, for a total transaction of $266,028.60.

Neurocrine Biosciences Stock Down 1.6 %

Shares of Neurocrine Biosciences stock opened at $115.02 on Monday. The company has a market capitalization of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The firm’s 50-day moving average price is $137.83 and its two-hundred day moving average price is $130.46.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently made changes to their positions in NBIX. Cetera Investment Advisers boosted its stake in shares of Neurocrine Biosciences by 7.9% in the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock valued at $979,000 after purchasing an additional 519 shares in the last quarter. CWM LLC boosted its stake in shares of Neurocrine Biosciences by 15.1% in the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock valued at $908,000 after purchasing an additional 1,035 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Neurocrine Biosciences by 29.3% in the 3rd quarter. Exchange Traded Concepts LLC now owns 7,964 shares of the company’s stock valued at $918,000 after purchasing an additional 1,803 shares in the last quarter. Creative Planning boosted its stake in shares of Neurocrine Biosciences by 12.3% in the 3rd quarter. Creative Planning now owns 12,999 shares of the company’s stock valued at $1,498,000 after purchasing an additional 1,426 shares in the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in shares of Neurocrine Biosciences by 12.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 14,590 shares of the company’s stock valued at $1,681,000 after purchasing an additional 1,639 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NBIX. Bank of America cut their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Morgan Stanley upped their price target on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Piper Sandler reaffirmed an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Finally, Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.